Detailed Abstract
[E-poster]
[E11] Reappraisal Of Single-port Approach For Laparoscopic Distal Pancreatectomy
Hyung Joon HAN1 , Sung-Ho KIM1 , Tae-Jin SONG*1 , Sang-Jin KIM1 , Il-Kwang HYUN1
1 HBP & Transplant Division, Korea Univ. ANSan Hospital, REPUBLIC OF KOREA
Background : Single-port laparoscopic surgery has been evaluated to be difficult and limited in complex surgery. We herein report our experiences on single-port laparoscopic distal pancreatectomy.
Methods : From March 2012 to March 2021, 41 cases of surgeries were performed and analyzed. The indication included benign or borderline malignant pancreatic tumors.
Results : Mean age was 58.5 years and the mean BMI was 23.7 kg/m2. The mean operation time was 259.7 minutes. Mean tumor size was 3.4 cm. Three cases were converted: Two were conventional laparoscopic and one was open approach. Spleen was preserved in 25 cases (61%). POPF complications occurred in six cases (14.6%). The mean hospital stay was 13.5 days. Clavian-Dindo complications over grade III was 8 cases (19.5%). The operation time had a significantly and continuously decreasing trend.
Conclusions : Single Port approach in distal pancreatectomy could be successfully performed in benign and borderline malignant pancreatic tumors.
Methods : From March 2012 to March 2021, 41 cases of surgeries were performed and analyzed. The indication included benign or borderline malignant pancreatic tumors.
Results : Mean age was 58.5 years and the mean BMI was 23.7 kg/m2. The mean operation time was 259.7 minutes. Mean tumor size was 3.4 cm. Three cases were converted: Two were conventional laparoscopic and one was open approach. Spleen was preserved in 25 cases (61%). POPF complications occurred in six cases (14.6%). The mean hospital stay was 13.5 days. Clavian-Dindo complications over grade III was 8 cases (19.5%). The operation time had a significantly and continuously decreasing trend.
Conclusions : Single Port approach in distal pancreatectomy could be successfully performed in benign and borderline malignant pancreatic tumors.
SESSION
E-poster
E-Session 12/03 ALL DAY